GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Sage Therapeutics Inc (NAS:SAGE) » Definitions » Cyclically Adjusted PB Ratio

Sage Therapeutics (Sage Therapeutics) Cyclically Adjusted PB Ratio : 0.64 (As of May. 16, 2024)


View and export this data going back to 2014. Start your Free Trial

What is Sage Therapeutics Cyclically Adjusted PB Ratio?

As of today (2024-05-16), Sage Therapeutics's current share price is $12.07. Sage Therapeutics's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2024 was $18.85. Sage Therapeutics's Cyclically Adjusted PB Ratio for today is 0.64.

The historical rank and industry rank for Sage Therapeutics's Cyclically Adjusted PB Ratio or its related term are showing as below:

SAGE' s Cyclically Adjusted PB Ratio Range Over the Past 10 Years
Min: 0.63   Med: 2   Max: 3.29
Current: 0.64

During the past years, Sage Therapeutics's highest Cyclically Adjusted PB Ratio was 3.29. The lowest was 0.63. And the median was 2.00.

SAGE's Cyclically Adjusted PB Ratio is ranked better than
72.45% of 646 companies
in the Biotechnology industry
Industry Median: 1.76 vs SAGE: 0.64

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

Sage Therapeutics's adjusted book value per share data for the three months ended in Mar. 2024 was $11.728. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is $18.85 for the trailing ten years ended in Mar. 2024.

Shiller PE for Stocks: The True Measure of Stock Valuation


Sage Therapeutics Cyclically Adjusted PB Ratio Historical Data

The historical data trend for Sage Therapeutics's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sage Therapeutics Cyclically Adjusted PB Ratio Chart

Sage Therapeutics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - 2.15 1.16

Sage Therapeutics Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.32 2.58 1.13 1.16 0.99

Competitive Comparison of Sage Therapeutics's Cyclically Adjusted PB Ratio

For the Biotechnology subindustry, Sage Therapeutics's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Sage Therapeutics's Cyclically Adjusted PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Sage Therapeutics's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Sage Therapeutics's Cyclically Adjusted PB Ratio falls into.



Sage Therapeutics Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

Sage Therapeutics's Cyclically Adjusted PB Ratio for today is calculated as

Cyclically Adjusted PB Ratio=Share Price/ Cyclically Adjusted Book per Share
=12.07/18.85
=0.64

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Sage Therapeutics's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2024 is calculated as:

For example, Sage Therapeutics's adjusted Book Value per Share data for the three months ended in Mar. 2024 was:

Adj_Book=Book Value per Share/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=11.728/131.7762*131.7762
=11.728

Current CPI (Mar. 2024) = 131.7762.

Sage Therapeutics Quarterly Data

Book Value per Share CPI Adj_Book
201406 -1.794 100.560 -2.351
201409 5.195 100.428 6.817
201412 4.757 99.070 6.327
201503 4.145 99.621 5.483
201506 7.596 100.684 9.942
201509 6.881 100.392 9.032
201512 6.026 99.792 7.957
201603 8.974 100.470 11.770
201606 8.019 101.688 10.392
201609 11.132 101.861 14.401
201612 9.900 101.863 12.807
201703 8.536 102.862 10.935
201706 6.956 103.349 8.869
201709 5.331 104.136 6.746
201712 11.320 104.011 14.342
201803 22.801 105.290 28.537
201806 23.126 106.317 28.664
201809 21.108 106.507 26.116
201812 18.405 105.998 22.881
201903 25.856 107.251 31.769
201906 23.371 108.070 28.498
201909 20.864 108.329 25.380
201912 18.209 108.420 22.132
202003 16.357 108.902 19.793
202006 14.247 108.767 17.261
202009 12.640 109.815 15.168
202012 35.541 109.897 42.617
202103 34.299 111.754 40.444
202106 32.831 114.631 37.741
202109 31.201 115.734 35.526
202112 29.337 117.630 32.865
202203 27.401 121.301 29.767
202206 25.329 125.017 26.698
202209 23.198 125.227 24.411
202212 21.049 125.222 22.151
202303 18.961 127.348 19.620
202306 16.462 128.729 16.852
202309 13.618 129.860 13.819
202312 13.316 129.419 13.558
202403 11.728 131.776 11.728

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Sage Therapeutics  (NAS:SAGE) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


Sage Therapeutics Cyclically Adjusted PB Ratio Related Terms

Thank you for viewing the detailed overview of Sage Therapeutics's Cyclically Adjusted PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Sage Therapeutics (Sage Therapeutics) Business Description

Traded in Other Exchanges
Address
215 First Street, Cambridge, MA, USA, 02142
Sage Therapeutics Inc is a clinical-stage biopharmaceutical company focused on brain health medicines. The company is targeting diseases and disorders of the brain with three key focus areas: depression, neurology and neuropsychiatry; also targeting two critical central nervous system, or CNS, receptor systems, GABA and NMDA. The GABA receptor family, which is recognized as the inhibitory neurotransmitter in the CNS, mediates downstream neurologic and bodily function via activation of GABAA receptors. The NMDA-type receptors of the glutamate receptor system are a excitatory receptor system in the CNS. Dysfunction in these systems is implicated in a broad range of CNS disorders.
Executives
Elizabeth Barrett director C/O SAGE THERAPEUTICS, INC., 215 FIRST STREET, CAMBRIDGE MA 02142
Jessica Federer director C/O SAGE THERAPEUTICS, INC., 215 FIRST STREET, CAMBRIDGE MA 02142
Jeffrey M Jonas director, officer: See Remarks ROBERTS SHERIDAN & KOTEL, 12 EAST 49TH STREET 30TH FL, NEW YORK NY 10017
Barry E Greene director C/O ACORDA THERAPEUTICS, 420 SAW MILL RIVER ROAD, ARDSLEY NY 10502
Laura Gault officer: Chief Medical Officer C/O SAGE THERAPEUTICS, INC., 245 FIRST STREET, SUITE 16, CAMBRIDGE MA 02142
George Golumbeski director C/O CELGENE CORP., 86 MORRIS AVENUE, SUMMIT NJ 07901
Christopher Benecchi officer: Chief Commercial Officer C/O SAGE THERAPEUTICS, INC., 215 FIRST STREET, CAMBRIDGE MA 02142
James M Frates director 88 SIDNEY ST, CAMBRIDGE MA 021394136
Biogen Inc. 10 percent owner 225 BINNEY STREET, CAMBRIDGE MA 02142
Biogen Ma Inc. 10 percent owner 225 BINNEY STREET, CAMBRIDGE MA 02142
Albert Robichaud officer: Chief Scientific Officer 215 FIRST STREET, CAMBRIDGE MA 02142
Michael Cloonan officer: Chief Business Officer C/O SAGE THERAPEUTICS, INC., 215 FIRST STREET, CAMBRIDGE MA 02142
Anne Marie Cook officer: General Counsel 101 MAIN STREET, SUITE 1850, CAMBRIDGE MA 02142
Steven M Paul director C/O ELI LITTY & CO, LIIY CORPORATE CENTER DC 1093, INDIANAPOLIS IN 46285
Kimi Iguchi officer: See Remarks 100 FOXBOROUGH BOULEVARD, SUITE 240, FOXBOROUGH MA 02035

Sage Therapeutics (Sage Therapeutics) Headlines

From GuruFocus

Sage Therapeutics to Present at Upcoming May Investor Conferences

By Business Wire Business Wire 05-03-2023